Report: Combination of health goods risky

Jul 22, 2007

A study in Canada has found the health industry has not adequately recognized the danger of pairing natural health products with prescription medication.

Research conducted at the University of Alberta featuring 132 pharmacists found that while nearly half had patients with possible side effects from the health combination, just 1.5 percent reported them to Canadian health officials, a release said Friday.

"The data show that adverse events are not being reported or are being under-reported at a dramatic rate," co-author of the study, Dr. Sunita Vohra, said. "Natural health products should be treated with due respect."

Vohra did point out that such harmful occurrences only represented a small portion of the overall use of natural health products in Canada.

The natural health products focused on in the study included vitamins, garlic, St. John's wort, Echinacea and minerals probiotics.

The group suggested using active surveillance and offering customers additional information to avoid such potentially harmful interactions.

Copyright 2007 by United Press International

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

21 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0